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Although there are multiple structures showing how ab T cell receptors (TCRs) specifically recognize anti-
genic peptides bound to the major histocompatibility complex (MHC) molecules (pMHC-I and pMHC-II),
we have little data on how TCRs interact with lipid-based antigens presented by members of the CD1 family.
Here, we review recent findings in the field of TCR recognition, including TCR-pMHC complexes and the
structure of a TCR in complex with CD1d-glycolipid. Collectively, these studies have revealed the versatility
of the TCR in recognizing the distinct yet evolutionarily related proteinaceous and lipid-presentingmolecules
of the immune system.Introduction
T cells bearing the ab T cell receptor (TCR) play a central role in
protective immunity by recognizing fragments of antigens in as-
sociation with specialized antigen-presenting molecules. Most T
cells are restricted to recognize and respond to antigens (Ags)
when they are presented by self-major histocompatibility com-
plex (MHC) molecules (Zinkernagel and Doherty, 1974) although
the structural basis of MHC-restriction remains enigmatic. More-
over, some T cells are not restricted to polymorphic MHC mole-
cules, nor do they recognize peptide antigens. For example, the
essentially monomorphic MHC class Ib molecules such as hu-
man leukocyte antigen (HLA)-E, which is involved principally in
innate immunity, also interact with TCRs (Rodgers and Cook,
2005; Sullivan et al., 2006). Similarly, natural killer T (NKT) cells
exhibit specificity for glycolipid antigens presented in the context
of CD1d (Godfrey et al., 2004). In contrast to our knowledge of
TCR recognition of peptide MHC (pMHC) complexes, our under-
standing of TCR-lipid-CD1 recognition, such as that associated
with NKT cells, is still very limited, and it is not yet clear whether
the emerging principles of TCR-pMHC recognition (discussed
below) will also apply to TCR recognition of these other ‘‘noncon-
ventional’’ Ags. Recent developments in the field of TCR-lipid-
mediated recognition have started to shed light on this question,
thus broadening our understanding on the adaptability of T cells
to recognize diverse antigens in association with evolutionary
related yet distinct Ag-presenting molecules. In this review, we
discuss emerging evidence that the TCR can employ different
binding strategies to suit different types of Ags, thus highlighting
the flexibility and adaptability of the TCR.
The ab T Cell Receptor
The process of intrathymic T cell development and selection
allows the host to accrue a vast repertoire of abTCRs that is gen-
erated via gene rearrangement between exons encoding the var-
iable (V) domains of the TCR; namely the V and junction (J) gene
segments that form the Va domain and the V, diversity (D), and J
gene segments that create the Vb domain (Starr et al., 2003).
Further diversity introduced at V-(N)-J, V-(N)-D, and D-(N)-J304 Immunity 28, March 2008 ª2008 Elsevier Inc.junctional regions (Cabaniols et al., 2001; Rock et al., 1994).
This diversity is manifested in the complementarity-determining
regions (CDRs), three each from the Va and Vb domains that
form the antigen-recognition site of the TCR. Despite TCR diver-
sity and its importance in protective immunity, restricted Va and/
or Vb usage, as well as conserved motifs within the CDR3 loops,
characterize the immune response to many defined peptide and
lipid-based antigens (Turner et al., 2006; Gras et al., 2008).
Whether the responding T cell repertoire results in a biased
TCR usage or not, a hallmark of the TCR is the specificity of
the interaction with defined antigens.
Peptide Presentation
The Ag-binding cleft of MHC class II (MHC-II) molecules is open
ended, enabling it to bind long peptides, whereas theMHC-I cleft
is pinched off at the N and C termini, generally constraining the
length of MHC-I peptides to 8–10 amino acids (Rudolph et al.,
2006) (Figures 1A and 1B). Nevertheless, MHC-I can present lon-
ger peptides that generally bulge centrally from the Ag-binding
cleft (Burrows et al., 2006; Speir et al., 2001). The HLA locus rep-
resents the most polymorphic region in the human genome, re-
flecting natural selection for enhanced protective immunity
against the many pathogenic organisms encountered by human
populations. In addition, the essentially monomorphic MHC-Ib
molecules can present peptides, although their repertoire of
peptides is generally more restricted than their polymorphic
MHC-Ia counterparts. HLA molecules can differ from each other
by only a single amino acid (‘‘micropolymorphism’’) or by more
than 30 amino acids (Marsh et al., 2005). These polymorphisms,
which are generally focused in the Ag-binding cleft, control the
size and diversity of the peptide repertoire presented by each
HLA molecule. For instance, HLA-B44 and HLA-DQ8 typically
bind peptides that prefer the amino acid glutamate as an anchor
residue (Henderson et al., 2007; Macdonald et al., 2003). Despite
such HLA-anchor-specific restraints, considerable variability in
the sequence and mode of peptide binding for any given HLA
molecule exists. For example, some HLA alleles can bind non-
conventional antigens such as posttranslationally modified
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reported to present oligosaccharides (Cobb et al., 2004),
although the subsequent mode of TCR recognition of such un-
usual epitopes is unknown. Accordingly, MHC polymorphism
can alter the pMHC landscape in a manner that can impact
profoundly on TCR recognition.
Lipid Presentation
Although it was originally thought that T cells only recognize pep-
tide antigens, it is now clear that a range of distinct lipid antigens
bind to the CD1 family and can be presented to T cells (Brigl and
Brenner, 2004; De Libero and Mori, 2006). The CD1 family has
been divided into two groups, in which group 1 CD1 molecules
(CD1a, CD1b, CD1c) are present in many mammalian species
Figure 1. Antigen-Binding Clefts of MHC-I, MHC-II, and CD1d
Antigen-binding clefts of HLA-B8 (A), HLA-DQ8 (B), and CD1d (C). Antigens
are colored green, and residues forming the ‘‘restriction triad’’ in MHC-I and
MHC-II are colored yellow. The equivalent ‘‘triad’’ residues on CD1d are also
colored yellow but are not contacted by the NKT TCR.but are absent in rodents, probably due to a large deletion of
this region (Dascher, 2007), whereas group 2 CD1 molecules
(CD1d) are present in both rodents and humans. CD1e is another
member of the family that does not fit neatly into either group; it
lacks a transmembrane domain and is thought to play an intra-
cellular trafficking role (De Libero and Mori, 2006). The CD1 fam-
ily members have been described asMHC-like and indeed share
significant secondary structural similarity to the MHC-I mole-
cules, including conserved disulfide bond arrangements and as-
sociation with b2-microglobulin (b2-m) (Figure 1C). However,
CD1 molecules are adapted to bind lipid-based Ags rather than
peptides (Gadola et al., 2002; Zajonc et al., 2003; Zeng et al.,
1997). Hence, in contrast to the hydrophilic Ag-binding cleft of
MHC-I molecules, the corresponding regions of CD1 molecules
are hydrophobic, lack H bonding sites, and comprise two to four
large internal channels (designated A0 and F0 pockets for CD1d
and CD1a and A0, F0, C0, and T0 channels for CD1b) (Moody et al.,
2005). In contrast to MHC-Ia molecules, members of the CD1
family are monomorphic yet are still able to bind a diverse array
of lipid-based antigens. For example, multiple structures of anti-
gen-bound CD1 family members have been reported, including
CD1b bound to three ligands (phosphatidylinositol, GM2 gangli-
oside, Glucose monomycolate) (Gadola et al., 2002; Batuwan-
gala et al., 2004), CD1a bound to sulfatide (Zajonc et al., 2003)
or mycobactin lipopeptide (Zajonc et al., 2005b), and CD1d
bound to a-Galactosyl ceramide (a-GalCer) (Koch et al., 2005;
Zajonc et al., 2005a), a-Galacturonosyl ceramide a-GalAGSL
(Wu et al., 2006), sulfatide (Zajonc et al., 2005c), phosphatidyl-
choline (Giabbai et al., 2005), and iGb3 (Zajonc et al., 2008). In
each case, the lipid base of the Ag is largely embedded in the hy-
drophobic cleft of CD1, whereas the polar head group protrudes
from the cleft, representing a potential antigenic target for CD1-
restricted T cells.
Peptide and Lipid Loading
Although MHC-I, MHC-II, and CD1 display remarkable similari-
ties in their Ag-binding cleft architecture, they deviate markedly
in the manner in which their respective antigenic cargo is loaded,
further emphasizing the functional differences of these Ag-
presenting molecules. The major source of peptides for MHC-I
presentation is via the proteasomal processing of peptides in
the cytoplasm, which are actively transported by the TAPmolec-
ular pump across the membrane of the ER and into its lumen [for
a recent review, see (Garbi et al., 2007)]. These peptides are then
subsequently loaded into the cleft of empty MHC-I molecules via
a coordinated series of events within a molecular machine
termed the peptide-loading complex (PLC). Optimization of the
MHC-I peptide cargo is mediated by tapasin, a key component
of the PLC (Williams et al., 2002). In contrast, MHC-II molecules
are chaperoned by the invariant chain that occludes their cleft
until they reach the endosomal compartments, where they ex-
change the class II-associated invariant chain peptide (CLIP)
for new peptides. Hence MHC-II molecules sample proteins
from membrane, secretory, cytoplasmic, and extracellular ori-
gins. Like MHC-I, peptide loading of MHC-II is further optimized
by the peptide-exchange function of the class II-like DM
molecule (Karlsson, 2005).
Similar to MHC-I, CD1 molecules are assembled in the ER in
association with b-2m, under the control of the chaperonesImmunity 28, March 2008 ª2008 Elsevier Inc. 305
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ulates disulfide bond formation) [for recent reviews see (Barral
and Brenner, 2007; De Libero and Mori, 2006)]. Newly synthe-
sized CD1 molecules are loaded with self-lipid antigens in the
ER, a process that is facilitated by lipid transfer proteins such
as microsomal triglyceride transfer protein (MTP) in the case of
CD1d (Dougan et al., 2005). These CD1-Ag complexes traffic
via the Golgi to the plasmamembrane, and subsequently recycle
via the endocytic pathway where they exchange lipid antigens,
thus allowing them to sample antigens that can be of endoge-
nous, exogenous, self, or foreign origins. Unique sorting motifs
in theCD1 cytoplasmic domains promote differential intracellular
trafficking of distinct CD1 isoforms, thus diversifying the intracel-
lular compartments that they sample (Barral and Brenner, 2007;
De Libero and Mori, 2006). CD1a traffics between early sorting
endosomes and the plasma membrane, whereas CD1b and
CD1d traffic between late endosomes and lysosomes and the
plasma membrane, and CD1c traffics through both the early
and the late endosomal system (Barral and Brenner, 2007; De
Libero andMori, 2006). Late endosomes and lysosomes provide
a specialized biochemical environment that orchestrates lipid
transfer and loading through optimal pH, glycosidase action,
and the function of lipid-transfer proteins like the saposins (Bar-
ral and Brenner, 2007; De Libero and Mori, 2006). Furthermore,
different lipid species localize to different cellular compartments
on the basis of their biophysical properties such as alkyl chain
length and saturation (Moody et al., 2002; Mukherjee et al.,
1999). Hence, like MHC-I and MHC-II molecules, the CD1 mole-
cules have developed a broadly based surveillance strategy that
samples endogenous and exogenous antigens. Although the an-
tigen-sampling mechanisms share some similarities with those
of conventional MHC molecules, there are clear differences in
the type of antigens and the compartments sampled, thus pro-
viding a separate system that alerts T cells to novel antigens;
however, this has evolved specifically to sample lipid-, rather
than protein-based molecules.
Evolutionary Relationship between MHC
and CD1 Molecules
MHC molecules are found in the cartilaginous-jawed fishes (tel-
eosts) such as sharks, with further diversification of these genes
having occurred during subsequent speciation. Despite some
attempts to identify orthologs of the CD1 family in teleosts,
they have not been found, although they have been identified
in birds. Thus, current evidence suggests that CD1 genes arose
later than MHC-I and emerged after teleosts but prior to the sep-
aration of birds and mammals. This separation is estimated to
have occurred 384million years ago (Dascher, 2007). In humans,
the MHC maps to chromosome 6, whereas the CD1 locus is lo-
cated on chromosome 1, and chickens have two CD1 genes that
both map to the MHC-I region (Maruoka et al., 2005; Miller et al.,
2005). This finding suggests that the CD1 genes evolved from
MHC-I genes by tandem duplication followed by translocation
of the CD1 locus prior to the mammalian radiation. The two
CD1 genes in chickens do not segregate into group 1 and group
2 CD1 isoforms, suggesting that this divergence arose later in
evolution. The ancestral relationship between MHC-I and CD1
genes establishes the basis for their analogous roles in immune
surveillance and their recognition by a shared pool of TCRs.306 Immunity 28, March 2008 ª2008 Elsevier Inc.Peptide Recognition
Despite the multitude of potential TCR and pMHC landscapes,
the TCR-pMHC interaction maintains remarkable specificity yet
exhibits very weak affinity (1–100 mM) (van der Merwe and Davis,
2003), and autoreactive TCRs typically exhibit evenweaker affin-
ity (200 mM) (Deng and Mariuzza, 2007). How this specificity is
achieved has begun to be addressed by structural studies of
TCR-pMHC complexes (Clements et al., 2006; Rudolph et al.,
2006; Deng and Mariuzza, 2007; Nicholson et al., 2005), with
a reasonable number of independent TCR-pMHC structures
(Reinherz et al., 1999; Tynan et al., 2005b; Tynan et al., 2007;
Garboczi et al., 1996; Garcia et al., 1998; Kjer-Nielsen et al.,
2003; Reiser et al., 2003; Reiser et al., 2000; Reiser et al., 2002;
Buslepp et al., 2003; Chen et al., 2005; Colf et al., 2007; Deng
et al., 2007; Ding et al., 1998; Feng et al., 2007; Hahn et al.,
2005; Li et al., 2005; Stewart-Jones et al., 2003; Hennecke et al.,
2000; Li et al., 2005; Maynard et al., 2005; Dai et al., 2008, in this
issue of Immunity) being determined, thereby permitting a broad
perspective to be gleaned from this data (Figures 2A–2E).
The TCR docking modes onto the pMHC surfaces are very
variable in nature, and it is now clear that no consensus ‘‘diago-
nal’’ or ‘‘orthogonal’’ docking mode exists between pMHC-I and
pMHC-II complexes, respectively. Nevertheless, a rough dock-
ing mode between the TCR-pMHC is preserved, in which the
Va domain is positioned over the a2 helix, and the N-terminal
end of the peptide and the Vb domain is positioned over the a1
helix and C-terminal end of the peptide (Clements et al., 2006;
Rudolph et al., 2006) (Figure 2A). Within this consensus footprint,
which can scan across the pMHC surface, the TCR-pMHC inter-
face is generally extensive (1200–2400 A˚2 buried surface area
[BSA]), although its shape complementarity is generally quite
poor, and this is consistent with the low affinity for the interac-
tion. Although the MHC surface generally dominates the interac-
tion with the TCR, one study has revealed that the TCR focus can
be more peptide centric (Tynan et al., 2005b) (Figure 2C). In ad-
dition, the individual contributions of the CDR loops to the inter-
action with the pMHC varies to such a degree between the differ-
ent TCR-pMHC complexes that the bipartisan view (Wu et al.,
2002), namely that the CDR1 and CDR2 loops contact the
MHC whereas the CDR3 loops contact the peptide, is rather
overstated. For example, the nongermline-encoded CDR3 can
play a prominent role in interacting with the MHC (Figure 3)
(Chen et al., 2005; Hahn et al., 2005; Kjer-Nielsen et al., 2003)
and conversely, the CDR1 and CDR2 loops have also been
shown to interact with the antigenic peptide in a number of differ-
ent TCR-pMHC complexes (Buslepp et al., 2003; Stewart-Jones
et al., 2003; Tynan et al., 2005b). In agreement with these obser-
vations, extensive mutagenesis studies at the TCR-pMHC inter-
face (Baker et al., 2001; Gagnon et al., 2005) have highlighted the
variability of the contributions of the CDR loops to the energetics
of the interaction. For example, in one system, the CDR1 and
CDR2 loops were shown to be the predominant driving force in
the interaction (Manning et al., 1998), whereas in another, the
CDR3 loops dictated the energetics of the interaction (Borg
et al., 2005) (Figure 3). Moreover, biophysical measurements
have shown that the TCR-pMHC interaction can either be en-
thalpically or entropically favored (Colf et al., 2007; Ely et al.,
2006; Miller et al., 2007; Willcox et al., 1999). Such observations
disguise the inherent bias TCRs have for MHC molecules and
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tant guiding hand in enablingMHC restriction, consistent with re-
cent observations from CD8CD4 mice (Van Laethem et al.,
2007). Nevertheless, not all TCRs are coreceptor dependent,
and a large number of biophysical and crystallographic studies
have shown that TCRs exhibit exquisite specificity for MHC in
the absence of coreceptors, highlighting the codependent evo-
lution of TCRs and MHC molecules. Moreover, Garcia and col-
leagues, as well as a recent study (Dai et al., 2008, in this issue
of Immunity), have observed a recurrent theme in the interactions
between MHC molecules and TCRs that use Vb8.2 (Feng et al.,
2007). In addition, some pMHC landscapes are considered to
represent challenging targets for TCR ligation, necessitating bi-
ased TCR usage, in which particular Va and/or Vb and or
CDR3 motifs have been observed to make distinct specificity-
Figure 2. Close-Up Views ofMHC-I, MHC-II,
and CD1d in Complex with TCR that
Highlight the Versatility in the TCR Docking
Strategies
(A) H-2Kb- 2C, the cognate interaction with the 2C
TCR (PDB ID 2CKB).
(B) H-2Ld-2C the alloreactive complex with the 2C
TCR (PDB ID 2E7L).
(C) HLA-B*3508-SB27, an example of how biased
TCRs can interact with atypical pMHC landscapes
(PDB ID 2AK4).
(D) HLA-E-KK50.4, an example of a MHC-Ib-TCR
complex (PDB ID 2ESV).
(E) HLA-DR2-Ob.1A12, an example of an auto-
reactive TCR-MHC-II complex that shows an un-
usual docking (PDB ID 1YMM). The a and b helices
of the MHC-II are colored light and dark blue, re-
spectively.
(F) CD1d-NKT15. The NKT TCR adopts an acute
docking mode in interacting with CD1d (PDB ID
2PO6).
The MHC and CD1d are shown in cyan, antigens
are colored green, and TCRs are red (a chain)
and magenta (b chain).
governing interactions (Miles et al.,
2005; Stewart-Jones et al., 2003; Turner
et al., 2006; Turner et al., 2005; Tynan
et al., 2005a). Furthermore, when one
evaluates the interactions made in all
TCR-pMHC structures determined to
date, three positions (termed the ‘‘restric-
tion triad’’) on theMHC-I andMHC-II mol-
ecule are invariably contacted by the
TCR, namely positions 65, 69, and 155
(in MHC-I), and this might represent a
minimal docking framework to enable
MHC restriction (Tynan et al., 2005b),
although this has yet to be tested in a
cellular context.
Structural investigations into autoreac-
tive and antitumor TCRs have highlighted
further versatility at the TCR-pMHC inter-
face. Namely, autoimmune TCRs tend to
exhibit unusual binding modes when
compared to the antimicrobial TCR-
pMHC complexes (Figure 2E). Such atyp-
ical binding modes tend to include a focus more toward the
N-terminal region of the peptide (Hahn et al., 2005) (Li et al.,
2005), and the interactions with the Ag appear suboptimal,
thereby providing a basis for their low affinity (200 mM), which
is also consistent with the need of these autoreactive TCRs to
escape negative selection. Interestingly, a recent report of a tu-
mor-specific MHC-II-restricted TCR has indicated an interaction
mode that appears to be a hybrid of some of the features of an-
timicrobial and autoreactive TCRs (Deng et al., 2007). However,
an important caveat to such observations is that there are rela-
tively few TCR-pMHC-II structures determined, and thus pres-
ently it is unclear whether such unusual docking topologies will
be restricted to autoreactive TCRs.
The exquisite versatility of the TCR has also been highlighted
by studies on altered peptide ligands (APLs) and howImmunity 28, March 2008 ª2008 Elsevier Inc. 307
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ations in the peptide can convert an agonist to an antagonist or
superagonist, yet the structural perturbations at the TCR-pMHC
interface are minimal, and how such subtle differences relate to
profound differences in signaling outcomes is still unclear
(Degano et al., 2000; Ding et al., 1999; Ely et al., 2005; Reid
et al., 1996). Second, polymorphism within the Ag-binding cleft
can alter the positioning of the MHC backbone, or the conforma-
tion and/or themobility of the peptide, and these effects can pro-
foundly affect the ability of the TCR to ‘‘see’’ a pMHCormarkedly
Figure 3. The Diversity of the Structural and Energetic Footprints on
TCRs
(A) The 2C TCR footprint on H-2Ld.
(B) The LC13 TCR footprint on HLA-B8.
(C) The NKT TCR footprint on CD1d.
Contact points of the respective complexes that do not contribute to the ener-
getic footprint are white, whereas the energetically important regions are red.
The remainder of the TCR is colored orange. The figure was generated with
structural and the respective alanine scanningmutational data. The 2C TCR in-
teraction is driven by the CDR1 and CDR2 loops, whereas the LC13 interaction
is more dependent on the nongermline-encoded CDR3 loops. The NKT TCR
requires both the CDR3a and CDR2b loops for recognition.308 Immunity 28, March 2008 ª2008 Elsevier Inc.alter the responding T cell repertoire (Miles et al., 2006; Tynan
et al., 2005c).
Plasticity of the CDR loops is an important factor enabling
TCRs to mold around structurally distinct pMHC landscapes
(Chen et al., 2005; Garcia et al., 1998; Garcia et al., 1996; Kjer-
Nielsen et al., 2002; Kjer-Nielsen et al., 2003). In general, the
pMHC surface is relatively fixed upon TCR ligation, with confor-
mational adjustments being restricted to side-chain movements
of the MHC or peptide to avoid steric clashes with the incoming
TCR or to improve shape complementarity, although malleability
in the peptide can be an important factor enabling TCR engage-
ment (Garboczi et al., 1996; Tynan et al., 2007). TCR plasticity
has also provided an understanding of the basis of TCR cross-
reactivity, whereby malleability of the CDR3 loops can be an im-
portant facet in a single TCR being able to recognize distinct
pMHC landscapes (Mazza et al., 2007; Reiser et al., 2003; Reiser
et al., 2000; Reiser et al., 2002). Moreover, in the case of two au-
toimmune complexes (Li et al., 2005; Maynard et al., 2005), the
lack of polar interactions between the peptide and the TCR
was consistent with a degenerate mode of recognition.
Despite the remarkable fine specificity of TCRs, some violate
the rule of MHC-restriction in that they can recognize nonself-
MHC and are termed alloreactive, whichmanifests itself clinically
in T cell-mediated transplant rejection and graft versus host dis-
ease. The 2C TCR recognizing nonself has highlighted the versa-
tility of the TCR in interacting with different pMHC landscapes
(Colf et al., 2007; Luz et al., 2002) (Figure 2B). Namely, despite
the similarities in the self- and nonself-pMHC surfaces, the 2C
TCR was observed to adopt two different docking strategies in
recognizing self- and nonself-MHC (Figures 2A and 2B), in which
the MHC, and not the peptide, appeared to be the main factor
in driving this alternative docking mode. The 2C TCR largely
focused on the differences between these pMHC landscapes,
using different interaction chemistries yet without invoking differ-
ing plasticity in the CDR loops. However, it seems likely that
other examples of T cell allorecognition will depend more on
contacts that are shared between the cognate and allogeneic
pMHC surfaces (Rossjohn and McCluskey, 2007).
In addition to TCR recognition of peptides bound to polymor-
phic MHC, recent studies have also highlighted the role of MHC
class Ib molecules, which are essentially monomorphic, in regu-
lating the adaptive immune responses to bacteria and viruses as
well as tumors and self-antigens (Rodgers and Cook, 2005;
Sullivan et al., 2006). In this regard, the structure of a TCR in
complex with HLA-E has revealed the basis of specificity for
the peptide-bound antigen and suggested the basis of HLA-E re-
striction (Hoare et al., 2006) (Figure 2D). However the generalities
of TCR recognition ofMHC-Ibmolecules are just as unclear, as is
whether there is a fundamental difference between MHC class
Ia- and class Ib-mediated recognition by a TCR.
Lipid Recognition: Group II CD1 Molecules
Although there have been a number of studies on CD1-restricted
T cell responses, the most extensively studied lipid-reactive T
cells are NKT cells, which are known to recognize a number of
different glycolipid antigens in association with CD1d. There
are two broad classes of NKT cells (type 1 and type 2), with
the vast majority of studies having focused on type 1 NKT cells
(hereafter referred to simply as NKT cells) that are defined by
Immunity
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Ja18 in mice or Va24-Ja18 in humans, and in each case, the
CDR3a region is also invariant at the amino acid level. The
TCR-b chain is biased toward Vb8.2, Vb7, or Vb2 expression in
mice and Vb11 in humans, but the CDR3b regions are hypervari-
able. NKT cells react strongly with the potent glycolipid agonist
molecule a-GalCer presented by CD1d (Kawano et al., 1997).
a-GalCer is a synthetic molecule that was originally derived
from marine sponge extracts that exhibited potent anticancer
potential in mice. When activated, NKT cells produce an array
of cytokines, which affords them the ability to influence immune
outcomes in a broad range of diseases, including cancer, auto-
immunity, allergy, and infection [reviewed in (Godfrey and
Kronenberg, 2004)]. NKT cells develop in the thymus as a result
of random TCR gene rearrangements generating a TCR that can
recognize CD1d (plus self-glycolipid antigen), which initiates the
NKT cell development sequence [reviewed in (Godfrey and
Berzins, 2007)]. Interestingly, in comparison to the TCR-pMHC
interaction, the NKT TCR-CD1d-a-GalCer interaction appears
to be of relatively high affinity, especially in the case of themouse
interaction, which is reported to exhibit nanomolar affinity (Cantu
et al., 2003; Sidobre et al., 2002). In stark contrast to MHC-
restricted T cells, NKT cells show reciprocal cross-species
reactivity, highlighting the evolutionary-conserved nature of
this interaction.
Recently, the structure of the human NKT TCR alone (Gadola
et al., 2006; Kjer-Nielsen et al., 2006), and bound to the CD1d-
a-GalCer complex (Borg et al., 2007), has been determined
(Figure 2F). Although the structures of the unliganded NKT
TCRs were similar to that of MHC-restricted TCRs, the NKT
TCR-CD1d-a-GalCer ternary complex revealed an unusual and
unanticipated docking strategy that differed from known TCR-
pMHC interactions because the TCR was tilted and exhibited
a parallel docking mode in relation to the Ag-binding cleft of
CD1d (Borg et al., 2007; Moody, 2007). The complex also re-
vealed a relatively small BSA at the interface, and moreover,
the CD1d equivalent of the TCR-pMHC restriction triad was not
involved in the NKT TCR-CD1d complex. The invariant TCR-
a chain dominated this interaction, whereas the role of the Vb
chain was restricted to the CDR2b loop interacting with CD1d
(Figure 3). In relation to the Vb8.2 ‘‘interaction codon,’’ it should
be noted, however, that this theme does not extend to NKT TCR-
CD1d recognition, as the Vb11- (Vb8.2- in mice) encoded CDR2b
loop of the NKT TCR interacted with a region on CD1d that was
structurally distinct from the equivalent interaction codon in
the MHC. The CDR1a loop interacted solely with the lipid
Ag, whereas the CDR3a loop played a central role, contacting
CD1d and the lipid Ag, consistent with the lack of NKT cells in
Ja18-deficient mice that are incapable of generating the invari-
ant TCR-a chain common to all NKT cells (Cui et al., 1997). Se-
quence and structural conservation between the human and
mouse invariant NKT TCRs are likely to underpin the reciprocal
cross-species reactivity. The extent of contacts of the NKT
TCR with the glycolipid head group provided a basis for the
specificity for a-GalCer, as well as indicated why closely related
analogs, such as b-GalCer, do not bind with high affinity to the
NKT TCR. Furthermore, the NKT TCR was observed to be rela-
tively rigid in interacting with the CD1d-a-GalCer, underscoring
the innate characteristics of this interaction.Analogous to MHC-bound APLs, there are several synthetic
agonist analogs of a-GalCer with remarkably distinct effects on
NKT cell function, suggesting altered TCR engagement charac-
teristics. The main examples are OCH (Miyamoto et al., 2001)
and C20:2 (Yu et al., 2005), both of which are remarkable in their
ability to bias the NKT cell response toward T helper 2 (Th2)
cytokine production. These molecules seem to represent better
ligands for inducing NKT cell-mediated immune suppressive ef-
fects, as has been demonstrated in several experimental sys-
tems (Chiba et al., 2004; Forestier et al., 2007; Ueno et al.,
2005). Conversely, a-C-GalCer biases the NKT cell response to-
ward Th1 cytokine production (Chiba et al., 2004; Coppieters
et al., 2007; Forestier et al., 2007; Schmieg et al., 2003; Teng
et al., 2007; Ueno et al., 2005). The reasons why these analogs
induce altered functional responses from NKT cells is unclear,
but altered TCR binding is one possibility. For example, the
more rigid glycosidic linkage of a-C-GalCer may impact the ori-
entation of the glycosyl head group and therefore TCR binding.
Alternatively, the pro-Th1-cytokine-inducing effects of this ana-
log may be due to increased resistance to enzymic glycosidic
degradation in vivo, thus resulting in different activation kinetics
of NKT cells rather than different TCR conformational changes
(Schmieg et al., 2003).
An unanswered question in the field is how the semi-invariant
NKT TCR has the ability to recognize diverse CD1d-restricted
Ags that include bacterial glycolipids as well as mammalian
self-glycolipids. Examples of bacterial glycolipids include the
a-glycuronosylceramides derived from Sphingomonas bacteria
and a-galactosyl-diacylglycerol derived from the spirocheteBor-
relia bergdorferi, which is the infectious agent for Lyme disease
(Kinjo et al., 2006; Kinjo et al., 2005; Mattner et al., 2005; Sriram
et al., 2005). Although these bacterial glycolipids are similar to
a-GalCer in that they possess an a-linked monoglycosyl head
group, the mammalian self-glycolipid, isoglobotrihexosylcera-
mide (iGb3) is remarkably different with the glycosyl head group
comprising three sugars, and it is unclear how the NKT TCR can
accommodate such a bulky moiety. Nevertheless, the NKT TCR-
CD1d-a-GalCer structure (Borg et al., 2007) provided some in-
sight into this conundrum, whereby the peripheral location of
the CDR3b loop, coupled with the hypervariability of the
CDR3b loop, was viewed as a potential mechanism that invoked
plasticity in recognizing diverse glycolipids. One intriguing possi-
bility is that the cavity that has been observed for all NKT TCR
structures described (Gadola et al., 2006; Kjer-Nielsen et al.,
2006) may accommodate more complex glycosyl head groups
such as that associated with iGb3 (Zajonc et al., 2008). Alterna-
tively, movement in the ligand per se, analogous to that of flexible
pMHC epitopes, may occur. Hints at the NKT TCR adaptability
arose from comparing the structures of human and mouse
CD1d-a-GalCer complexes, where an interspecies polymor-
phism at position 153 (human, Trp 153; mouse, Gly 155) notably
alters the orientation of the a-GalCer head group (Godfrey et al.,
2005). Given the interspecies crossreactivity of the NKT TCR,
this implies that some degree of flexibility is likely to exist at
the NKT TCR-CD1d interface. It is also worth noting that the
semi-invariant NKT TCR has the challenging task of not reacting
with any of the vast number of polymorphic pMHC molecules it
encounters at a population level. Although this property of the
NKT TCR may be helped by the lack of coreceptors on manyImmunity 28, March 2008 ª2008 Elsevier Inc. 309
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CDR3b regions is as much about avoidance of self-pMHC reac-
tivity as modulation of glycolipid reactivity. It will be important to
test this notion in the future.
Further insight into this adaptability of the NKT TCR to recog-
nize distinct CD1d-restricted Ags arose from an extensive series
of mouse NKT TCR mutagenesis experiments that not only un-
derscored the importance of the CDR1a, CDR3a, and CDR2b
loops in interacting with CD1d but also showed that this mode
of interaction is conserved between the different CD1d-
restricted ligands (Scott-Browne et al., 2007). As such, it was
considered that the NKT TCR acted as an innate pattern-recog-
nition receptor. In contrast, a study from McCarthy et al. (2007)
reported how glycolipids with different lipid-tail lengths altered
the affinity for the NKT TCR, with themechanism possibly occur-
ring through alterations in the juxtapositioning of the a helices of
CD1d above the F0 pocket, the major point of contact with the
NKT TCR. Such observations are supported by marked confor-
mational changes that were observed between loaded and un-
loaded CD1d molecules (Koch et al., 2005), a concept that res-
onates with subtle variations in MHC structure impacting TCR
recognition. Moreover, it is considered that some TCR-b chains
might better accommodate certain glycolipid antigens. For ex-
ample, whereas all mouse NKT cells are capable of recognizing
the CD1d-a-GalCer complex, regardless of Vb usage, some
studies have shown that, under limiting conditions, TCR-Vb8
provides the highest affinity recognition of this complex (Schu-
mann et al., 2003). In contrast, recognition of the CD1d-iGb3
complex appears to be favored by NKT cells expressing Vb7
over those expressing Vb8.2 and Vb2 (Schumann et al., 2006;
Wei et al., 2006). In one intriguing study, where the invariant
TCR-a chain was artificially expressed in association with
a broad range of TCR-b chains, many different TCR-Vb chains
not normally associated with NKT cells supported recognition
of CD1d a-GalCer, whereas only Vb7, Vb8, and Vb2 supported
recognition of the mammalian glycolipid antigen iGb3 (Wei
et al., 2006). These data suggested that iGb3 or a similar antigen
might be involved in shaping the TCR-b repertoire of developing
NKT cells during intrathymic selection.
Whether CD1 restricted T cells other than type 1 NKT cells ex-
hibit similar structural characteristics as observed with the NKT
TCR-CD1d-a-GalCer complex is unclear. Type 2 NKT cells,
present in mice and humans, are also CD1d restricted, but
they do not express the invariant TCR-a chain that characterizes
type 1 NKT cells, and they do not react with a-GalCer [reviewed
in (Godfrey et al., 2004)] but may respond to other glycolipid an-
tigens such as sulfatide (Ambrosino et al., 2007; Halder et al.,
2007; Jahng et al., 2004; Zajonc et al., 2005c) and nonlipidic ar-
omatic hydrocarbon rings (Van Rhijn et al., 2004). Type 2 NKT
cells are less well-characterized because of a lack of reagents
to easily study them, but they are biased toward Vb8.2 usage,
and they express other forms of invariant TCR-a chains, includ-
ing Va3-Ja9 and Va8 (Godfrey et al., 2004). At least some type 2
NKT cells do not require lysosomal trafficking of CD1d, support-
ing the concept that the antigens they recognize are distinct from
those recognized by type 1 NKT cells (Chiu et al., 1999; Chiu
et al., 2002). There is very little known about type 2 NKT cell
TCR interactions, but given the quasi-invariant nature of these
receptors, it is tempting to speculate that they also adopt a non-310 Immunity 28, March 2008 ª2008 Elsevier Inc.conventional binding strategy to CD1d plus antigen, similar to
the type 1 NKT cell TCR.
Lipid Recognition: Group I CD1 Molecules
Humans carry an even more diverse repertoire of lipid-antigen-
reactive T cells, including CD4CD8, CD4+, and CD8+ T cells
that are restricted to the group 1 CD1 antigens (CD1a, CD1b,
and CD1c). A very broad range of foreign and self-lipid-based
antigens can be presented by group 1 CD1 molecules and pre-
sented to T cells, including, but not limited to: glycosphingolipids
such as sulfatide (CD1a, CD1b, and CD1c); lipopeptides such as
mycobactin (CD1a); mycobacterial-cell-wall-derived lipids such
as mycolic acids and phosphatidylinositol mannosides (PIMs)
(CD1b); and single alkyl chain phosphoisoprenoids and phos-
phomycoketides (CD1c) [reviewed in (Moody et al., 2005; Zajonc
and Wilson, 2007)]. Studies of TCR interactions with these anti-
gens are limited; however, in contrast to CD1d-restricted NKT
cells, group 1 CD1-restricted T cells seem to express highly di-
verse TCRs. Structural models have been proposed for CD1a-
lipopeptide-TCR complex (Zajonc et al., 2005b) and CD1b-
mycolic acid-TCR complex (Grant et al., 1999). These suggested
a diagonal orientation where the TCR CDR3 hypervariable re-
gions both contact the CD1-antigen complex, which was
supported by TCR mutagenesis studies (Grant et al., 2002).
However, given that similar models of the NKT TCR-CD1d-
a-GalCer complex proved to be inaccurate, direct investigation
of CD1-lipid-TCR complex crystals is clearly necessary if we
are to draw any general conclusions about how TCRs interact
with lipid antigens in the context of CD1 family members.
Conclusions
The growing database of TCR structures has highlighted a myr-
iad of ways in which a TCR can accommodate diverse land-
scapes, which is dictated by the requirement of fidelity for a given
interaction. The TCR has shown remarkable adaptability to en-
able MHC-restricted recognition, although we do not as yet
have a clear view on the basis of MHC restriction. Nevertheless,
some insight into MHC-restriction has emerged, and the contin-
ued pursuit of unique TCR-pMHC complexes, accompanied by
biophysical analyses, is required for the field to build a compre-
hensive collection of structures that will allow further under-
standing of the interaction. It will also be valuable to ascertain
how MHC polymorphism can have such profound effects on
TCR recognition. In addition, although we have had the first
glimpse of how a TCR recognizes nonself-MHC molecules,
more examples of cross- and alloreactivity are required for the
field to gain amore complete understanding of TCR promiscuity.
Given the apparent redundancy of the building blocks that en-
compass immune recognition of protein and lipid-based Ags,
namely a TCR recognizing antigens presented by MHC or the
evolutionary-related CD1, one may have predicted that the fun-
damental basis of TCR-pMHC recognition would be mirrored by
TCR-CD1 recognition. The first structural snapshot of a TCR-
CD1d complex has revealed this not to be the case, however,
with notable features contrasting the present generalities of
TCR-pMHC recognition. Whether the atypical binding mode
will be maintained when the NKT TCR recognizes diverse
CD1d-lipid complexes is unclear. Indeed, how TCRs bind to
the CD1 family in general remains to be established. Although
Immunity
ReviewsomeMHC-restricted TCRs are alloreactive, it is unclear whether
CD1-restricted TCRs will similarly exhibit such promiscuity. The
NKT TCR is an example of biased TCR usage directed against
a monomorphic antigen-presenting molecule that not only reso-
nates with innate recognition but also shares some aspects with
biased TCR usage that is observed in adaptive immunity. Both
situations arise as a consequence of specificity-governing de-
mands and from an evolutionary perspective; it will be of interest
to ascertain the mechanisms underpinning primordial TCR
recognition of Ags.
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